Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MVA-BN
Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-BN
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
The three lots of MVA-BN induced similar antibody responses, meeting the study's primary endpoint, while the favourable safety profile was also confirmed without severe adverse reactions.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CLP based Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Recipient: AdaptVac
Deal Size: Undisclosed Upfront Cash: $4.6 million
Deal Type: Collaboration July 22, 2020
Details:
Bavarian Nordic has been granted license of AdaptVac’s proprietary capsid virus like particle (cVLP) technology for coronaviruses, including the COVID-19 indication.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MVA-BN Filo vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-BN-Filo
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Janssen Pharmaceutical
Deal Size: $13.9 million Upfront Cash: Undisclosed
Deal Type: Agreement June 18, 2020
Details:
Bavarian Nordic will manufacture and deliver bulk drug substance of its MVA-BN Filo vaccine, which Janssen has licensed as part of its Ebola vaccine regimen.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MVA-BN-WEV
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2020
Details:
Data from the study showed that the vaccine was well tolerated and immunogenic across all dose groups.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
